Examkin

Question

Difficulty: HardSubstance-Related and Addictive Disorders

A 29-year-old man comes to the outpatient clinic to establish care following successful completion of a 28-day residential substance use treatment program. He has a long history of severe opioid use disorder and alcohol use disorder. The patient reports that he has maintained complete abstinence from all opioids and alcohol for the past 24 days. He states, 'I am determined to stay clean this time, but my cravings for both heroin and alcohol are overwhelming.' His past psychiatric history is significant for major depressive disorder. During a previous attempt at outpatient treatment two years ago, he exhibited poor medication adherence and was ultimately discharged from the practice after admitting to diverting his prescribed sublingual buprenorphine-naloxone. Liver function tests obtained at the residential facility last week were within normal limits. Vital signs today are within normal limits. Physical examination shows no signs of intoxication or withdrawal. Which of the following is the most appropriate pharmacotherapy to prevent relapse in this patient?

  1. Intramuscular extended-release naltrexoneAnswer
  2. B
    Sublingual buprenorphine-naloxone
  3. C
    Oral naltrexone
  4. D
    Oral methadone
  5. E
    Oral acamprosate

Answer

Intramuscular extended-release naltrexone
Intramuscular extended-release naltrexone is a mu-opioid receptor antagonist that is highly effective for patients with both opioid and alcohol use disorders. Because it is administered monthly, it overcomes the patient's history of poor daily adherence. Furthermore, as an antagonist, it has zero diversion potential, directly addressing his prior history of selling his medication. Finally, the patient is an ideal candidate because he has been fully abstinent from opioids for 24 days, safely surpassing the required 7-14 day opioid-free window, thereby eliminating the risk of precipitated withdrawal.

Step-by-Step Solution

1
Identify the patient's active diagnoses and current abstinence status.
The patient has both severe opioid use disorder (OUD) and alcohol use disorder (AUD), and has been abstinent from all substances for 24 days.
Establishing the specific substance use disorders and the duration of abstinence dictates which pharmacologic agents are safe and indicated.
2
Analyze psychosocial barriers to treatment success based on patient history.
The patient has a documented history of poor daily medication adherence and diversion of prescribed sublingual buprenorphine-naloxone.
Past behavior strongly predicts future behavior; therapies requiring daily compliance or carrying high diversion potential are contraindicated or highly suboptimal here.
3
Evaluate the pharmacologic options against the clinical parameters.
Naltrexone treats both OUD and AUD. The extended-release intramuscular formulation bypasses daily adherence issues and has zero diversion potential. The 24-day abstinence period means naltrexone can be initiated without precipitating withdrawal.
Synthesizing the need for dual-diagnosis coverage, guaranteed delivery (IM), and lack of street value points directly to intramuscular naltrexone as the safest and most effective choice.

Key Concept

Intramuscular extended-release naltrexone is a highly effective, dual-purpose pharmacotherapy for patients with both opioid and alcohol use disorders. It is particularly indicated for patients with a history of medication nonadherence or diversion, provided they have been completely opioid-free for at least 7 to 14 days to avoid precipitated withdrawal.
Rate this question

Topics

Substance-Related and Addictive Disorders

More questions from this topic